Welcome to our dedicated page for Capricor Therapeutics SEC filings (Ticker: CAPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Capricor Therapeutics Inc (NASDAQ: CAPR) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Capricor is a Delaware corporation whose common stock trades on The Nasdaq Capital Market under the symbol CAPR, as disclosed in its Form 8-K reports. These filings are a primary source for understanding the company’s financial condition, clinical and regulatory milestones, and material corporate events.
Through this page, readers can review current and historical filings such as Form 8-K reports that announce quarterly financial results, material regulatory updates and other significant developments. For example, Capricor has filed 8-Ks describing the receipt of a Complete Response Letter from the FDA for its Biologics License Application for Deramiocel, subsequent regulatory meetings, and press releases detailing financial results for specific quarters.
Filings also reference key aspects of Capricor’s business, including its focus on Deramiocel, an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy, and its listing of common stock on The Nasdaq Capital Market. These documents may discuss how the company reports results of operations and financial condition, as well as the status of clinical programs and regulatory interactions that are material to the company.
On Stock Titan, each new CAPR filing is captured from EDGAR and paired with AI-powered summaries to help explain the contents in plain language. Users can quickly see the purpose of a filing, identify whether it relates to earnings, regulatory correspondence, financings or other corporate events, and then drill down into the full text if more detail is needed. This structure allows investors and researchers to navigate Capricor’s SEC disclosure record efficiently while retaining access to the underlying official documents.
Capricor Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is attached as Exhibit 99.1. The company states the release is being furnished, not filed, and therefore is not subject to Section 18 liability and will not be incorporated by reference into other Exchange Act filings unless expressly stated. The filing also includes a Cover Page Interactive Data File (inline XBRL) as Exhibit 104. The report identifies Capricor common stock trading as CAPR on The Nasdaq Capital Market and is signed by CEO Linda Marbán, Ph.D.. Investors should review Exhibit 99.1 for the detailed financial figures because the 8-K text here provides only the notice of the release.